Detalhe da pesquisa
1.
Axicabtagene ciloleucel versus standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume.
Blood
; 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38557775
2.
The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients.
Blood
; 143(11): 983-995, 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37979133
3.
Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.
Blood
; 2024 04 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38657242
4.
Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients.
Blood
; 2024 04 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38669626
5.
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med
; 387(24): 2220-2231, 2022 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36507690
6.
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
N Engl J Med
; 386(4): 351-363, 2022 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34904799
7.
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
N Engl J Med
; 386(7): 629-639, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34904798
8.
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
Blood
; 141(14): 1675-1684, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36542826
9.
Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis.
Blood
; 140(24): 2584-2593, 2022 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36122385
10.
Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study.
Blood
; 139(15): 2338-2346, 2022 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34936697
11.
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.
Blood
; 140(21): 2248-2260, 2022 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35839452
12.
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
Haematologica
; 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38385243
13.
Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.
Future Oncol
; 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38547003
14.
Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study.
Br J Haematol
; 201(2): 256-266, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36740991
15.
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Lancet
; 399(10343): 2294-2308, 2022 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35717989
16.
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.
Blood
; 137(7): 877-887, 2021 02 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33181832
17.
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
Blood
; 137(5): 600-609, 2021 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33538797
18.
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.
Blood
; 137(17): 2307-2320, 2021 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33211799
19.
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
Blood
; 137(25): 3495-3506, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33598678
20.
Lack of reproducibility of histopathological features in MYC-rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium.
Histopathology
; 82(7): 1105-1111, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36849712